1. Cell Cycle/DNA Damage Cytoskeleton Apoptosis
  2. Microtubule/Tubulin Apoptosis
  3. Verubulin

Verubulin (MPC-6827) is a microtubule-disrupting agent with potent and broad-spectrum in vitro and in vivo cytotoxic activities, and acts as a promising candidate for the treatment of multiple cancer types.

For research use only. We do not sell to patients.

Verubulin Chemical Structure

Verubulin Chemical Structure

CAS No. : 827031-83-4

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 88 In-stock
Solution
10 mM * 1 mL in DMSO USD 88 In-stock
Solid
5 mg USD 80 In-stock
10 mg USD 135 In-stock
50 mg USD 475 In-stock
100 mg USD 760 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Verubulin:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Verubulin (MPC-6827) is a microtubule-disrupting agent with potent and broad-spectrum in vitro and in vivo cytotoxic activities, and acts as a promising candidate for the treatment of multiple cancer types[1].

IC50 & Target

Microtubule[1]

Cellular Effect
Cell Line Type Value Description References
A-375 IC50
0.7 nM
Compound: Verubulin
Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
[PMID: 34406768]
A375/TxR IC50
0.7 nM
Compound: Verubulin
Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
[PMID: 34406768]
A-431 IC50
0.9 nM
Compound: 1
Cytotoxicity against human A-431 cells assessed as reduction in cell viability by Sulforhodamine B assay
Cytotoxicity against human A-431 cells assessed as reduction in cell viability by Sulforhodamine B assay
[PMID: 33647840]
A549 IC50
0.003 μM
Compound: EP128495
Growth inhibition of human A549 cells after 48 hrs by MTT assay
Growth inhibition of human A549 cells after 48 hrs by MTT assay
[PMID: 29509413]
A549 IC50
0.004 μM
Compound: MPC-6827
Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay
[PMID: 29673981]
A549 IC50
0.005 μM
Compound: MPC6827
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
[PMID: 30093295]
A549/CDDP IC50
0.009 μM
Compound: EP128495
Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay
Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay
[PMID: 29509413]
BJ IC50
0.015 μM
Compound: EP128495
Antiproliferative activity against human BJ cells after 48 hrs by MTT assay
Antiproliferative activity against human BJ cells after 48 hrs by MTT assay
[PMID: 29509413]
HCT-116 EC50
0.003 μM
Compound: 6h, EP128495,MPC-6827, azixa
Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay
Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay
[PMID: 19296653]
HCT-116 IC50
0.004 μM
Compound: EP128495
Growth inhibition of human HCT116 cells after 48 hrs by MTT assay
Growth inhibition of human HCT116 cells after 48 hrs by MTT assay
[PMID: 29509413]
HCT-116 IC50
0.005 μM
Compound: MPC-6827
Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay
[PMID: 29673981]
HCT-116 GI50
0.006 μM
Compound: 6h, EP128495,MPC-6827, azixa
Growth inhibition of human HCT116 cells after 48 hrs by celltiter assay
Growth inhibition of human HCT116 cells after 48 hrs by celltiter assay
[PMID: 19296653]
HCT-116 IC50
0.009 μM
Compound: MPC6827
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
[PMID: 30093295]
HCT-116 IC50
4.3 nM
Compound: 5; MPC-6827
Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay
[PMID: 27213819]
HeLa IC50
0.005 μM
Compound: EP128495
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
[PMID: 29509413]
HeLa IC50
0.006 μM
Compound: MPC-6827
Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay
[PMID: 29673981]
HeLa IC50
0.007 μM
Compound: MPC6827
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
[PMID: 30093295]
HeLa IC50
1.5 nM
Compound: 1
Cytotoxicity against human HeLa cells over expressing WT-beta3 assessed as reduction in cell viability by Sulforhodamine B assay
Cytotoxicity against human HeLa cells over expressing WT-beta3 assessed as reduction in cell viability by Sulforhodamine B assay
[PMID: 33647840]
HeLa IC50
2 nM
Compound: 1
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by Sulforhodamine B assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by Sulforhodamine B assay
[PMID: 33647840]
HepG2 IC50
0.005 μM
Compound: MPC-6827
Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
[PMID: 29673981]
HepG2 IC50
0.005 μM
Compound: EP128495
Growth inhibition of human HepG2 cells after 48 hrs by MTT assay
Growth inhibition of human HepG2 cells after 48 hrs by MTT assay
[PMID: 29509413]
HepG2 IC50
0.006 μM
Compound: MPC6827
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
[PMID: 30093295]
HepG2 IC50
4.6 nM
Compound: 5; MPC-6827
Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
[PMID: 27213819]
L02 IC50
0.013 μM
Compound: EP128495
Antiproliferative activity against human LO2 cells after 48 hrs by MTT assay
Antiproliferative activity against human LO2 cells after 48 hrs by MTT assay
[PMID: 29509413]
LoVo IC50
0.008 μM
Compound: EP128495
Growth inhibition of human LoVo cells after 48 hrs by MTT assay
Growth inhibition of human LoVo cells after 48 hrs by MTT assay
[PMID: 29509413]
M14 IC50
1 nM
Compound: Verubulin
Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
[PMID: 34406768]
MCF7 IC50
0.011 μM
Compound: EP128495
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 29509413]
MDA-MB-231 IC50
0.008 μM
Compound: MPC-6827
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
[PMID: 29673981]
MDA-MB-231 IC50
0.008 μM
Compound: EP128495
Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay
Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay
[PMID: 29509413]
MDA-MB-435 IC50
1.7 nM
Compound: 1
Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability by Sulforhodamine B assay
Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability by Sulforhodamine B assay
[PMID: 33647840]
MGC-803 IC50
0.008 μM
Compound: EP128495
Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
[PMID: 29509413]
NCI-H1299 EC50
0.006 μM
Compound: 1e
Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs by HTS assay
Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs by HTS assay
[PMID: 19464890]
RKO IC50
0.003 μM
Compound: EP128495
Growth inhibition of human RKO cells after 48 hrs by MTT assay
Growth inhibition of human RKO cells after 48 hrs by MTT assay
[PMID: 29509413]
RKO IC50
0.005 μM
Compound: MPC6827
Antiproliferative activity against human RKO cells after 48 hrs by MTT assay
Antiproliferative activity against human RKO cells after 48 hrs by MTT assay
[PMID: 30093295]
SK-OV-3 IC50
2.2 nM
Compound: 1
Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability by Sulforhodamine B assay
Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability by Sulforhodamine B assay
[PMID: 33647840]
SK-OV-3 IC50
2.6 nM
Compound: 1
Cytotoxicity against human SK-OV-3 cells over expressing MDR1-6/6 assessed as reduction in cell viability by Sulforhodamine B assay
Cytotoxicity against human SK-OV-3 cells over expressing MDR1-6/6 assessed as reduction in cell viability by Sulforhodamine B assay
[PMID: 33647840]
SK-OV-3 IC50
3.2 nM
Compound: 5; MPC-6827
Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay
Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay
[PMID: 27213819]
SNU-398 EC50
0.002 μM
Compound: 6h, EP128495,MPC-6827, azixa
Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay
Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay
[PMID: 19296653]
SNU-398 GI50
0.003 μM
Compound: 6h, EP128495,MPC-6827, azixa
Growth inhibition of human SNU398 cells after 48 hrs by celltiter assay
Growth inhibition of human SNU398 cells after 48 hrs by celltiter assay
[PMID: 19296653]
T47D EC50
0.002 μM
Compound: 6h, EP128495,MPC-6827, azixa
Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay
Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay
[PMID: 19296653]
T47D EC50
0.002 μM
Compound: 1e
Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay
Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay
[PMID: 19464890]
T47D GI50
0.006 μM
Compound: 6h, EP128495,MPC-6827, azixa
Growth inhibition of human T47D cells after 48 hrs by celltiter assay
Growth inhibition of human T47D cells after 48 hrs by celltiter assay
[PMID: 19296653]
U-251 IC50
2.8 nM
Compound: 1
Cytotoxicity against human U-251 cells assessed as reduction in cell viability by Sulforhodamine B assay
Cytotoxicity against human U-251 cells assessed as reduction in cell viability by Sulforhodamine B assay
[PMID: 33647840]
Clinical Trial
Molecular Weight

279.34

Formula

C17H17N3O

CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

CC1=NC(N(C2=CC=C(OC)C=C2)C)=C3C=CC=CC3=N1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (357.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.5799 mL 17.8993 mL 35.7987 mL
5 mM 0.7160 mL 3.5799 mL 7.1597 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (7.45 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (7.45 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.34%

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.5799 mL 17.8993 mL 35.7987 mL 89.4967 mL
5 mM 0.7160 mL 3.5799 mL 7.1597 mL 17.8993 mL
10 mM 0.3580 mL 1.7899 mL 3.5799 mL 8.9497 mL
15 mM 0.2387 mL 1.1933 mL 2.3866 mL 5.9664 mL
20 mM 0.1790 mL 0.8950 mL 1.7899 mL 4.4748 mL
25 mM 0.1432 mL 0.7160 mL 1.4319 mL 3.5799 mL
30 mM 0.1193 mL 0.5966 mL 1.1933 mL 2.9832 mL
40 mM 0.0895 mL 0.4475 mL 0.8950 mL 2.2374 mL
50 mM 0.0716 mL 0.3580 mL 0.7160 mL 1.7899 mL
60 mM 0.0597 mL 0.2983 mL 0.5966 mL 1.4916 mL
80 mM 0.0447 mL 0.2237 mL 0.4475 mL 1.1187 mL
100 mM 0.0358 mL 0.1790 mL 0.3580 mL 0.8950 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Verubulin
Cat. No.:
HY-14907
Quantity:
MCE Japan Authorized Agent: